Printer Friendly

NEOCRIN ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER

 IRVINE, Calif., June 8 /PRNewswire/ -- Neocrin Co., a biomedical company developing a bioartificial pancreas for the treatment of insulin-dependent diabetes, announced today the appointment of Thomas P. O'Hara to the position of vice president Finance and Administration, and chief financial officer.
 O'Hara, 42, has over 15 years of executive management experience including responsibilities in accounting, finance, information systems, administration and human resources. He has expertise raising capital and establishing financial systems and procedures to support the operational growth of companies ranging from early-stage development ventures to mature, publicly held entities. Over the course of his career, O'Hara has been responsible for a variety of financing initiatives including equity/debt financing, mergers, partnerships. private placements and public offerings.
 O'Hara was formerly vice president Finance/Human Resources, chief financial officer and treasurer for Vitarel Microelectronics Inc. of San Diego. Prior to his tenure with Vitarel, O'Hara served as a financial/management consultant to several high technology and emerging growth companies in the San Diego area, providing knowledge from his diverse background as founder and president of a start-up venture as well as from management positions held with Fortune 500 companies. He holds a master's degree in finance from Keller Graduate School of Management, Chicago.
 "Tom is an excellent addition to Neocrin's senior management team," commented Greg Dane, the newly appointed president and chief operating officer of Neocrin. "His broad expertise in financing growth companies combined with his business experience in both public and private settings will be a tremendous asset to our operations as we proceed forward."
 Neocrin Co. is a private, development-stage biomedical company focusing on the development and commercialization of innovative products to treat insulin-dependent diabetes mellitus (also known as Type I diabetes). Development efforts are currently concentrated on the bioartificial pancreas, an implantable device capable of regulating blood glucose levels over sustained periods. Founded in 1992 through a joint venture between Baxter Healthcare Corp. and TranCel, the company is located in Irvine.
 -0- 6/8/93
 /CONTACT: Greg Dane of Neocrin, 714-727-1942; or Sylvia Wheeler of Russell-Welch, 415-312-0700, for Neocrin/


CO: Neocrin Co.; Baxter Healthcare Corp.; TranCel ST: California IN: MTC SU: PER

TM-GT -- SF001 -- 6381 06/08/93 09:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 8, 1993
Words:363
Previous Article:COSTCO WHOLESALE REPORTS SALES
Next Article:ZITEL AND DATA GENERAL ANNOUNCE AGREEMENT TO MAKE CLARIION STORAGE SYSTEMS AVAILABLE TO UNISYS MARKET
Topics:


Related Articles
CAMPBELL SOUP NAMES CHIEF FINANCIAL OFFICER
BAXTER AND TRANCEL FORM NEW COMPANY TO FOCUS ON DIABETES RESEARCH
CYTOTHERAPEUTICS AND NEOCRIN ANNOUNCE AGREEMENT TO MERGE DIABETES PROGRAMS
DNX NAMES BAXTER EXECUTIVE TO NEW BOARD SEAT
CYTOTHERAPEUTICS AND NEOCRIN COMPLETE AGREEMENT TO COMBINE DIABETES PROGRAMS
CYTOTHERAPEUTICS REPORTS YEAR END RESULTS
I.I.S. INTELLIGENT INFORMATION SYSTEMS LIMITED ANNOUNCES APPOINTMENT OF NEW CFO
KATHLEEN A. COTE NAMED TO COMPUTERVISION BOARD OF DIRECTORS
Neocrin Presents Diabetes Program at Hambrecht & Quist Healthcare Conference
SGI Makes Key Management Appointments.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters